Cipla Ltd. News and Updates

Name: Latest research reports of Cipla Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Sharekhan

Keep track of all breaking news on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

29 Oct 2024

1516.15

0.27%

to see Rapid results content

Cipla Ltd.

29 Oct 2024

1516.15

0.27%

Cipla's drops over 3% ahead of Q2FY25 results; know what analysts expect

Business Standard

Shares of Cipla dropped 3.55 per cent at Rs 1,450 per share on the BSE in Tuesday's intraday trade

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

29 Oct 2024

1516.15

0.27%

Meaningful new launches to drive growth

Buy: Cipla Ltd.

Target

Sharekhan

Cipla’s revenue reached Rs. 7,051 crore, reflecting a 7% y-o-y increase and a 6% q-o-q rise, meeting our expectations.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

16 Oct 2024

1516.15

0.27%

Cipla, Alkem eye Rs 4,000 crore stake in India's largest stent manufacturer

Business Standard

India's largest stent manufacturer, Sahajanand Medical Technologies is also reportedly exploring a public listing on the domestic market

Cipla Ltd. is trading above its 100 day SMA of 1478.1

Cipla Ltd.

11 Oct 2024

1516.15

0.27%

Cipla Share Price Falls After Chinese Rival Eats Into Cancer Drug Opportunity

NDTV Profit

While Citi has maintained its 'buy' call for Cipla, it noted that a further delay in resolving issues at the Goa facility resolution will diminish the opportunity.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

25 Sep 2024

1516.15

0.27%

Cipla To Buy Out Local Partner's Stake In Chinese Subsidiary For Over Rs 42 Crore

NDTV Profit

Cipla Jiangsu was incorporated in China in Aug. 2019 as a joint venture between Cipla (EU) and Xidi.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

04 Sep 2024

1516.15

0.27%

Change at Cipla, as MK Hamied resigns and son Kamil re-enters the drugmaker

Business Line

The developments involving Cipla's promoter family come even as reports suggested, as recently as last year, that members of the promoter family were looking to sell their stake

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

MK Hamied steps down as Cipla's Vice Chairman on account of age, health

Business Standard | 03 Sep 2024

Cipla Ltd.

02 Sep 2024

1516.15

0.27%

Cipla management outlines new focus areas for the future

Business Line

Promoter stake sale this year was towards social efforts, management tells shareholders

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

02 Aug 2024

1516.15

0.27%

Improving visibility in North America’s sales to aid in growth

Accumulate: Cipla Ltd.

Recommendation

KRChoksey

The Q1FY25 performance was slightly below estimates with Cipla’s sales/Gross Profits/EBITDA and PAT for Q1FY25 deviating by -3.2%/-1.6%/-3.2%/-2.3% from our estimates. It was due to weaker than expected performance in SAGA and API partially offset by marginally higher than estimated, US (+3.2%) and Emerging Markets (+3.8%).

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

Cipla Ltd.

29 Jul 2024

1516.15

0.27%

Don't go by market cap, go stock-specific; pharma may be an outperformer: Sandip Sabharwal

Economic Times

Sandip Sabharwal recommended a company-specific strategy over midcap or largecap classifications in light of high market valuations, suggesting a 15% cash reserve. He discussed Birla's impact on the jewellery sector and praised Cipla's quarterly performance. Sabharwal noted the potential for pharma stocks to outperform due to limited current investment in the sector.

Cipla Ltd. has an average target of 1707.30 from 11 brokers.

No results found

Is Cipla Ltd. worth buying?

585 Votes:

Buy 75.56%

Sell 14.19%

Hold 10.26%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf